---
schema_version: "secwatch.filing_event.v1"
accession: "0000875320-23-000029"
form_type: "8-K"
ticker: "VRTX"
cik: "0000875320"
company_name: "VERTEX PHARMACEUTICALS INC / MA"
filed_at: "2023-11-06T23:59:59+00:00"
generated_at: "2026-06-08T21:42:14.750428+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vertex Q3 product revenue $2.48B (+6% YoY); raises FY2023 guidance to ~$9.85B

## Summary
- Product revenue $2.48B (+6% YoY); U.S. $1.55B (+7%), ex-U.S. $929M (+6%).
- FY2023 product revenue guidance raised to ~$9.85B (from $9.7-9.8B); opex guidance unchanged.
- Exa-cel PDUFA for SCD Dec 8, 2023; BLA Priority Review; EU/UK reviews ongoing.
- Phase 3 data for vanzacaftor triple and VX-548 acute pain expected early 2024; Phase 2 neuropathic pain data late 2023.
- Cash and marketable securities $13.6B at Sep 30, 2023.

## SEC filing metadata
- accession: 0000875320-23-000029
- form_type: 8-K
- ticker: VRTX
- cik: 0000875320
- company_name: VERTEX PHARMACEUTICALS INC / MA
- filed_at: 2023-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/875320/000087532023000029/0000875320-23-000029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/875320/000087532023000029/vrtx-20231106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000875320-23-000029
- JSON: https://secwatch.observer/filing/0000875320-23-000029.json
- Plain text: https://secwatch.observer/filing/0000875320-23-000029.txt

## Key facts
- Earnings Releases
  VERTEX PHARMACEUTICALS INC / MA updated its full year 2023 guidance (raised).
  - Period: full year 2023
  - Guidance: raised
  - Result: guidance update
  source text: Vertex today raised its full year 2023 CF product revenue guidance to approximately $9.85 billion.
  evidence_url: https://www.sec.gov/Archives/edgar/data/875320/000087532023000029/0000875320-23-000029-index.htm
- Earnings Releases
  VERTEX PHARMACEUTICALS INC / MA reported third quarter ended September 30, 2023 results: revenue $2.48 billion. Guidance raised.
  - Period: third quarter ended September 30, 2023
  - Revenue: $2.48 billion
  - Guidance: raised
  - Result: reported results
  source text: as shall be expressly set forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Vertex Reports Third Quarter 2023 Financial Results — Product revenue of $2.48 billion, a 6% increase compared to Q3 2022 — — Company raises full year 2023 product revenue guidance to approximately $9.85 billion — — U.S. FDA Advisory Committee meeting for exa-cel
  evidence_url: https://www.sec.gov/Archives/edgar/data/875320/000087532023000029/0000875320-23-000029-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.